Why AI Stock HeartFlow Triumphed on Thursday A key FDA-cleared analysis tool earned professional accolades for its utility.
This Family Office Acquired $148 Million of Karman Stock as Shares Tripled Since February IPO One family office fund just made Karman its biggest reported equity bet—here’s what long-term investors should take from the move.
Billionaire Family Office Acquires $65 Million of HeartFlow as Stock Jumps 70% From IPO A billionaire family office has made a big bet on a newly public AI-driven heart diagnostics company—here’s what long-term investors should take from the move.
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter
Biotech Stock Gets Booted in Latest Fund Update Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock Bain Capital completely exited its position in Disc Medicine stock during the third quarter
Why Bain Capital Is Selling Shares of This Biotech Stock Now Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.
Where Innovation Meets the Heart: Stanford’s New Position in HeartFlow Stanford just bought into HeartFlow. Here is what caught Stanford’s eye and what investors need to know about HeartFlow’s early trajectory and long-term potential.
